Shopping Cart
- Remove All
Your shopping cart is currently empty
Eribulin (B1939) is a nonpaclitaxel microtubule kinetic inhibitor with anticancer activity that inhibits polymerization of microtubule protein subunits by preventing lengthening and shortening of microtubules during cell division.Eribulin is used in the study of metastatic breast cancer and solid tumors.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 500 μg | $283 | In Stock | |
| 1 mg | $347 | In Stock | |
| 5 mg | $513 | In Stock | |
| 10 mg | $828 | In Stock | |
| 25 mg | $1,230 | In Stock | |
| 50 mg | $1,650 | In Stock | |
| 100 mg | $2,220 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $798 | In Stock |
| Description | Eribulin (B1939) is a nonpaclitaxel microtubule kinetic inhibitor with anticancer activity that inhibits polymerization of microtubule protein subunits by preventing lengthening and shortening of microtubules during cell division.Eribulin is used in the study of metastatic breast cancer and solid tumors. |
| In vitro | In LM8 and Dunn cells, Eribulin inhibited cell proliferation in a dose-dependent manner at concentrations of 0, 1, 10, and 100 nM for 72 hours[1]. |
| In vivo | In 4-week-old C3H/HeN mice injected with LM8 cells, Eribulin (1 mg/kg; intravenous injection, once a week for 2 weeks) suppressed primary tumor growth and induced apoptosis in tumor cells. It also reduced the occurrence of lung metastasis and led to a decrease in body weight[1]. |
| Synonyms | ER-086526, E7389, B1939 |
| Molecular Weight | 729.90 |
| Formula | C40H59NO11 |
| Cas No. | 253128-41-5 |
| Smiles | [H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2 |
| Relative Density. | 1.29 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (137.01 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (6.85 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.